Last $2.36 USD
Change Today -0.06 / -2.48%
Volume 5.2K
AXGN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

axogen inc (AXGN) Snapshot

Open
$2.39
Previous Close
$2.42
Day High
$2.47
Day Low
$2.29
52 Week High
12/31/13 - $5.20
52 Week Low
08/12/14 - $2.11
Market Cap
41.2M
Average Volume 10 Days
12.3K
EPS TTM
$-0.94
Shares Outstanding
17.5M
EX-Date
01/27/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AXOGEN INC (AXGN)

Related News

No related news articles were found.

axogen inc (AXGN) Related Businessweek News

No Related Businessweek News Found

axogen inc (AXGN) Details

AxoGen, Inc. operates as a medical technology company. It focuses on advancing the science and commercialization of peripheral nerve repair solutions. It offers a range of surgical nerve repair solutions, including Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. The company’s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It procures and processes its tissue products in the United States, Canada, Italy, Austria, the United Kingdom, the Netherlands, Israel, and Switzerland. AxoGen, Inc. is headquartered in Alachua, Florida.

73 Employees
Last Reported Date: 03/6/14

axogen inc (AXGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $314.5K
Co-Founder and Vice President
Total Annual Compensation: $183.6K
Senior Vice President of Business Development...
Total Annual Compensation: $251.6K
Senior Vice President of Sales
Total Annual Compensation: $314.6K
Senior Vice President of Business Strategy & ...
Total Annual Compensation: $231.1K
Compensation as of Fiscal Year 2013.

axogen inc (AXGN) Key Developments

John McLaughlin Resigns as Member of the Board of Directors of AxoGen, Inc

On August 20, 2014, John McLaughlin delivered the notice of his resignation as a member of the Board of Directors of AxoGen, Inc. effective as of the date of the notice. The Board accepted Mr. McLaughlin’s notice of resignation. Mr. McLaughlin had served as a member of the Board since October 2012.

AxoGen, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Second Half Year of 2014

AxoGen, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $4,214,193 compared to $2,862,289 a year ago. Loss from operations was $2,297,744 compared to $2,194,329 a year ago. Net loss available to common shareholders was $3,741,471 or $0.21 basic and diluted per share compared to $3,457,799 or $0.31 basic and diluted per share a year ago. The gross margin improvement is due to changes in product mix and implementation of product price increases. For the six months period, the company reported revenues of $7,352,449 compared to $5,005,221 a year ago. Loss from operations was $5,288,886 compared to $4,517,883 a year ago. Net loss available to common shareholders was $7,981,036 or $0.62 basic and diluted per share compared to $6,895,309 or $0.46 basic and diluted per share a year ago. Net cash used for operating activities was $5,719,999 compared to $5,163,736 a year ago. Purchase of property and equipment was $283,476 compared to $45,315 a year ago. Acquisition of intangible assets was $30,305 compared to $39,060 a year ago. Based on strong performance in the first half of 2014 and current sales momentum, the company expects a stronger second half of the year. As a result it is increasingly confident that it will achieve original revenue target for 2014 of $16 million while maintaining gross margins of at least 75%.

AxoGen, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 10:55 AM

AxoGen, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 10:55 AM. Venue: Le Parker Meridien, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXGN:US $2.36 USD -0.06

AXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $74.55 USD -0.15
Integra LifeSciences Holdings Corp $49.27 USD -0.41
Stryker Corp $83.40 USD -0.06
View Industry Companies
 

Industry Analysis

AXGN

Industry Average

Valuation AXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AXOGEN INC, please visit www.axogeninc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.